Member Info for Saxondale

The Lyophilised patent .

You'll have to read it all and make your own minds up if its relevant

Another requirement, especially for the drug products for use in the treatment of ARDS, is that the drug product has to be available in an emergency. Consequently, there is a need for stable lyophilised pharmaceutical formulations comprising IFN-beta 1a having long shelf life and preserving their pharmaceutical utility, and especially if freeze-dried, requiring careful control of dosing and in use stability during administration. These requirements are necessary for compounds administered intravenously, as the patient gets exposed to the drug instantly.

https://patents.justia.com/patent/10293030

?
https://patents.justia.com/patent/7534423

Will it be a cytokine storm in a teacup today , or will I be lighting a large cigar later ?

I'll go with Big as that being the best bet . theres a patent for the freeze drying , and its more detailed than i could absorb .
So even though we will prove ourselves , others may also in their fields , so we get a cut of all the others action .
It's been there all the time - just needed the approvals to get the drugs to need that particular mechanism for quick and fast distribution in a bulk amount never imagined .
It'll be the two ton cherry on top of the already enormous cake .
Either that - or after 6000 posts Zen will now just disappear to leave us all hanging

He either knows something about a distribution / packaging agreement/patent application , but I've scoured the internet for 2 hours and just gone round in circles .
So my second hunch is that he is just buying up all the shares so there's none left .
Either way it seems to be working

Something in the riddle last night .
Faron had patented a new freeze dried method of manufacturing Traumakine.
That product would have 1-2 yr shelf life - and be ok under room temps
Rentchler would have to make serious upgrades to the active ingredient process .
Whether any of those 3 facts are relevant who knows - but the SP is going up :-)

Just been offered £4

The power of Zen

Nasdaq up 10%

All going to plan .
11,000 ounces of gold in stock .
so they just earned about an extra $1m by just sitting on it for a month.
Nice work if you can get it

Probably got naff all to do with what Zens talking about , but while I had my Columbo hat on I had another look down the Clevegen cohorts .
At the bottom of the list are 3 cohorts that are entering phase II trials - all for Vaccination .
The Pertussis one is for what is described as a highly contagious respiratory disease( albeit bacterial )
Also one for ' hard to vaccinate diseases'
And one for TB
Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.

Maybe some interested parties have been eyeing up Clevegen as a coronavirus prospect too ?

Anyway - enough of that - lets see what happens today , and don't blame old Zen if its nothing , cos things never happen exactly as people predict.

Never seen Zen quite as excited . Got me too on this one .
Keep your powder dry Zen mate , let it play out , and have the last word if it does - you'd deserve it !

Managed to grab a grand at £3.79 .
Needed quick fingers this afternoon !
Another Carlsberg RNS and the timing !

Been musing on whether this REMAP trial may open doors for Faron with Clevegen & the secret weapon .
Many of the hospitals that are connected with REMAP are top notch academic institutes , dealing in Cancer research and other cutting edge trials etc too .
Obviously Faron have their existing sites from phase 1/2/3 trials , but would be interesting how influential some of these partner sites would be for future expansion & even funding .
Markku wants to chill with Dr Angus and a beer when this is over ( at a reasonable distance obviously )

Hummingbird can never be accused of not letting you buy on the dips .
So many opportunities over the last 2 years .

REMAP twitter - happy to get additional funding for REMAP through APRISE - one of their Australian partners who got $2 million more for COVID 19 research .
Also REMAP Canada now launched in sites in Quebec and Ontario - with many more to launch across Canada .
Also fully funded by Canadian Govt.
Faron are an integral part of this .

On the other side - Trump pulls plug on WHO funding . say no more

backing up Traumakine - this is the pipeline page for their programs .

17 potential partner slots for the cancer immunity drug therapy alone .
Discussions ongoing . Hand strengthening after every update .
Funded for 2020 - no rush to give it away
But there comes a point when the results start to become irresistible to a potential partner.

Small float - hence the volatility . I've only held for a year - many have held for a lot longer .

https://www.faron.com/pipeline

Volume is 8k today so far - not exactly a landslide .
Good chance to top up , or just switch off and wait for an RNS

Not a bad write up - HUM : We think gold operations here are running extremely well currently and expect a strong 1Q result in the coming days (last year on 16th April), most likely the company's strongest quarter yet, likely a positive catalyst. The balance sheet has historically been burdened by high levels of debt but this will turn to net cash around mid-year 2020 for the first time helping reduce investor risk significantly. After this, cash generation for shareholders ramps fast. Management recently reset 2020 guidance and put in place various targets, a 5-year plan, and incentive structure around these including bonuses. Alongside this there have also been recent new share purchases by management during the 1Q, a relatively rare event in recent times and we view this action as a positive signal for Q1 and 2020 as a whole. Annualising Q4 2019 production (it is somewhat seasonal so not necessarily a good extrapolation) of 33,892oz gives 135,568oz production for 2020 which is well ahead of 125,000oz 2020 guidance, giving some comfort it could be exceeded. For 2020 the exploration budget has been significantly expanded and there is a clear focus on wanting to extend the existing mine life which we think will be successful as the year progresses. This is our favorite of the 5 shares discussed here and hence we would make it the largest holding in a weighted basket. We think a doubling of the share price over a year is a realistic goal.

I think someone mentioned before that Mali has a median age of about 17-18 yrs old - very young population . Average lifespan for a male is about 59 years .
So in that respect - Covid is an old persons disease to a greater extent- so its seems logical it would have less of an impact on such a young population - despite there lack of decent modern healthcare etc .

Another reason why REMAP is so much better than an FDA trial :

Taken from REMAP Canada website -

Modification of the primary end-point, so that information is available more quickly

Description of the statistical model that will be used to analyse data for patients with proven or suspected pandemic infection

Description of changes to statistical thresholds for declaring an intervention to be equivalent, superior, or inferior to another

Specification of pathways that permit the Data Safety Monitoring Board to liaise directly with public health authorities if REMAP-CAP produces results that are of relevance to public health